JP4603487B2 - リチウム塩を用いた表面増感ラマン分光法の化学増感 - Google Patents
リチウム塩を用いた表面増感ラマン分光法の化学増感 Download PDFInfo
- Publication number
- JP4603487B2 JP4603487B2 JP2005518574A JP2005518574A JP4603487B2 JP 4603487 B2 JP4603487 B2 JP 4603487B2 JP 2005518574 A JP2005518574 A JP 2005518574A JP 2005518574 A JP2005518574 A JP 2005518574A JP 4603487 B2 JP4603487 B2 JP 4603487B2
- Authority
- JP
- Japan
- Prior art keywords
- metal
- sample
- raman spectroscopy
- raman
- substrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000001069 Raman spectroscopy Methods 0.000 title claims description 75
- 239000000126 substance Substances 0.000 title claims description 9
- 206010070834 Sensitisation Diseases 0.000 title description 8
- 230000008313 sensitization Effects 0.000 title description 8
- 229910003002 lithium salt Inorganic materials 0.000 title description 2
- 159000000002 lithium salts Chemical class 0.000 title description 2
- 239000000758 substrate Substances 0.000 claims description 59
- 229910052751 metal Inorganic materials 0.000 claims description 52
- 239000002184 metal Substances 0.000 claims description 51
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 claims description 45
- 239000002082 metal nanoparticle Substances 0.000 claims description 43
- 238000000034 method Methods 0.000 claims description 39
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 23
- 229910052709 silver Inorganic materials 0.000 claims description 23
- 239000004332 silver Substances 0.000 claims description 23
- 239000012491 analyte Substances 0.000 claims description 18
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 18
- 239000002105 nanoparticle Substances 0.000 claims description 16
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 13
- 229910052737 gold Inorganic materials 0.000 claims description 13
- 239000010931 gold Substances 0.000 claims description 13
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 11
- 229910052802 copper Inorganic materials 0.000 claims description 11
- 239000010949 copper Substances 0.000 claims description 11
- 239000002773 nucleotide Substances 0.000 claims description 10
- 125000003729 nucleotide group Chemical group 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 229910052782 aluminium Inorganic materials 0.000 claims description 9
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 9
- 238000004458 analytical method Methods 0.000 claims description 9
- 229910052697 platinum Inorganic materials 0.000 claims description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 102000039446 nucleic acids Human genes 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 239000002207 metabolite Substances 0.000 claims description 6
- 239000002777 nucleoside Substances 0.000 claims description 6
- 229910021426 porous silicon Inorganic materials 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 108091034117 Oligonucleotide Proteins 0.000 claims description 5
- -1 cofactors Substances 0.000 claims description 5
- 150000007523 nucleic acids Chemical class 0.000 claims description 5
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 239000000975 dye Substances 0.000 claims description 4
- 125000003835 nucleoside group Chemical group 0.000 claims description 4
- 230000002285 radioactive effect Effects 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- 102000019034 Chemokines Human genes 0.000 claims description 3
- 108010012236 Chemokines Proteins 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 3
- 102000003886 Glycoproteins Human genes 0.000 claims description 3
- 108090000288 Glycoproteins Proteins 0.000 claims description 3
- 102000004895 Lipoproteins Human genes 0.000 claims description 3
- 108090001030 Lipoproteins Proteins 0.000 claims description 3
- 102000004108 Neurotransmitter Receptors Human genes 0.000 claims description 3
- 108090000590 Neurotransmitter Receptors Proteins 0.000 claims description 3
- 108091093037 Peptide nucleic acid Proteins 0.000 claims description 3
- 108091000054 Prion Proteins 0.000 claims description 3
- 102000029797 Prion Human genes 0.000 claims description 3
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 3
- 239000013566 allergen Substances 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 235000014633 carbohydrates Nutrition 0.000 claims description 3
- 231100000357 carcinogen Toxicity 0.000 claims description 3
- 239000003183 carcinogenic agent Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000000084 colloidal system Substances 0.000 claims description 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 239000002360 explosive Substances 0.000 claims description 3
- 239000000194 fatty acid Substances 0.000 claims description 3
- 229930195729 fatty acid Natural products 0.000 claims description 3
- 150000004665 fatty acids Chemical class 0.000 claims description 3
- 150000004676 glycans Chemical class 0.000 claims description 3
- 239000000380 hallucinogen Substances 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 239000002917 insecticide Substances 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 239000003471 mutagenic agent Substances 0.000 claims description 3
- 231100000707 mutagenic chemical Toxicity 0.000 claims description 3
- 235000015097 nutrients Nutrition 0.000 claims description 3
- 229920001542 oligosaccharide Polymers 0.000 claims description 3
- 150000002482 oligosaccharides Chemical class 0.000 claims description 3
- 239000002574 poison Substances 0.000 claims description 3
- 231100000614 poison Toxicity 0.000 claims description 3
- 229920001282 polysaccharide Polymers 0.000 claims description 3
- 239000005017 polysaccharide Substances 0.000 claims description 3
- 239000002096 quantum dot Substances 0.000 claims description 3
- 235000000346 sugar Nutrition 0.000 claims description 3
- 239000003053 toxin Substances 0.000 claims description 3
- 231100000765 toxin Toxicity 0.000 claims description 3
- 108700012359 toxins Proteins 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- 239000002699 waste material Substances 0.000 claims description 3
- 229910021423 nanocrystalline silicon Inorganic materials 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims 11
- 239000007864 aqueous solution Substances 0.000 claims 10
- 238000001237 Raman spectrum Methods 0.000 claims 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 2
- 102000053602 DNA Human genes 0.000 claims 2
- 229940035674 anesthetics Drugs 0.000 claims 2
- 229940125717 barbiturate Drugs 0.000 claims 2
- 238000002082 coherent anti-Stokes Raman spectroscopy Methods 0.000 claims 2
- 239000003344 environmental pollutant Substances 0.000 claims 2
- 239000003193 general anesthetic agent Substances 0.000 claims 2
- 238000000881 hyper Raman spectroscopy Methods 0.000 claims 2
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 2
- 231100000719 pollutant Toxicity 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 238000001945 resonance Rayleigh scattering spectroscopy Methods 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 1
- 238000004611 spectroscopical analysis Methods 0.000 description 42
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 239000003623 enhancer Substances 0.000 description 12
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 8
- 229910052710 silicon Inorganic materials 0.000 description 8
- 239000010703 silicon Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 238000001514 detection method Methods 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 4
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 238000004416 surface enhanced Raman spectroscopy Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- KHWCHTKSEGGWEX-UHFFFAOYSA-N deoxyadenylic acid Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(O)=O)O1 KHWCHTKSEGGWEX-UHFFFAOYSA-N 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002923 metal particle Substances 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 239000002585 base Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000005670 electromagnetic radiation Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229920006254 polymer film Polymers 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000001235 sensitizing effect Effects 0.000 description 2
- 229910001961 silver nitrate Inorganic materials 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- KHWCHTKSEGGWEX-RRKCRQDMSA-N 2'-deoxyadenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(O)=O)O1 KHWCHTKSEGGWEX-RRKCRQDMSA-N 0.000 description 1
- JBRZTFJDHDCESZ-UHFFFAOYSA-N AsGa Chemical compound [As]#[Ga] JBRZTFJDHDCESZ-UHFFFAOYSA-N 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 229910001218 Gallium arsenide Inorganic materials 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 229910052581 Si3N4 Inorganic materials 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000003486 chemical etching Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000002575 chemical warfare agent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002772 conduction electron Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000002019 doping agent Substances 0.000 description 1
- 230000005288 electromagnetic effect Effects 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- UJXZVRRCKFUQKG-UHFFFAOYSA-K indium(3+);phosphate Chemical compound [In+3].[O-]P([O-])([O-])=O UJXZVRRCKFUQKG-UHFFFAOYSA-K 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000000608 laser ablation Methods 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- HBMJWWWQQXIZIP-UHFFFAOYSA-N silicon carbide Chemical compound [Si+]#[C-] HBMJWWWQQXIZIP-UHFFFAOYSA-N 0.000 description 1
- 229910010271 silicon carbide Inorganic materials 0.000 description 1
- HQVNEWCFYHHQES-UHFFFAOYSA-N silicon nitride Chemical compound N12[Si]34N5[Si]62N3[Si]51N64 HQVNEWCFYHHQES-UHFFFAOYSA-N 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 238000000479 surface-enhanced Raman spectrum Methods 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01J—MEASUREMENT OF INTENSITY, VELOCITY, SPECTRAL CONTENT, POLARISATION, PHASE OR PULSE CHARACTERISTICS OF INFRARED, VISIBLE OR ULTRAVIOLET LIGHT; COLORIMETRY; RADIATION PYROMETRY
- G01J3/00—Spectrometry; Spectrophotometry; Monochromators; Measuring colours
- G01J3/28—Investigating the spectrum
- G01J3/44—Raman spectrometry; Scattering spectrometry ; Fluorescence spectrometry
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/65—Raman scattering
- G01N21/658—Raman scattering enhancement Raman, e.g. surface plasmons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
- C12Q1/6825—Nucleic acid detection involving sensors
Description
Claims (21)
- ラマン分光法により、水溶液中の標的検体を分析する段階を有し、
前記ラマン分光法は、塩化リチウムによって活性化された金属ナノ粒子によって増感され、
前記金属ナノ粒子が、銀、金、白金、銅、及びアルミニウムからなるグループから選択された金属を含む、
方法。 - 前記標的検体が、前記塩化リチウムで活性化された金属ナノ粒子を有する溶液中に配置される請求項1に記載の方法。
- 前記標的検体が、前記塩化リチウムで活性化された金属ナノ粒子を有する基質上に配置される請求項1に記載の方法。
- 前記基質は、金属ナノ粒子島状膜から構成される、または、金属被覆ナノ粒子が形成された基質から構成される、請求項3に記載の方法。
- 前記金属ナノ粒子は、金ナノ粒子あるいは銀ナノ粒子の金属コロイドから構成される、請求項3に記載の方法。
- 前記標的検体と前記金属ナノ粒子と前記塩化リチウムとを含む水溶液が、金属層がその上に配置されている基質に加えられる、請求項1に記載の方法。
- 前記ラマン分光法が、表面増感ラマン分光法、表面増感共鳴ラマン分光法、ハイパーラマン分光法、及びコヒーレントアンチストークスラマン分光法からなるグループから少なくとも1つ以上選択される請求項1に記載の方法。
- 前記標的検体が、アミノ酸、ペプチド、ポリペプチド、タンパク質、糖タンパク、リポタンパク質、ヌクレオシド、ヌクレオチド、オリゴヌクレオチド、核酸、デオキシリボース核酸、リボース核酸、ペプチド核酸、糖、炭水化物、オリゴ糖、多糖類、脂肪酸、脂質、ホルモン、代謝体、サイトカイン、ケモカイン、受容体、神経伝達物質、抗原、アレルゲン、抗体、基質、代謝体、共同因子、阻害物質、薬物、調合剤、栄養素、プリオン、毒素、毒薬、火薬、殺虫剤、化学兵器、バイオハザード剤、バクテリア、ウイルス、放射性元素、ビタミン、複素環芳香族化合物、発がん性物質、突然変異原、麻酔薬、アンフェタミン、バルビツール酸塩、幻覚剤、廃棄物、汚染物質、量子ドット、あるいは染料からなるグループから選択される請求項1に記載の方法。
- 前記標的検体が、ヌクレオシド、ヌクレオチド、オリゴヌクレオチド、核酸、アミノ酸、ペプチド、ポリペプチド、及びたんぱく質からなるグループから選択される請求項1に記載の方法。
- ラマン分光法により試料を分析する方法であって、
金属ナノ粒子を含む水溶液を準備する段階と、
前記水溶液に塩化リチウムを加えて、増感した金属ナノ粒子溶液を生成する段階と、
前記試料中の標的検体をラマン分光法により検出できるように、前記試料を、前記増感した金属ナノ粒子溶液に接触させる段階と、
前記試料のラマンスペクトルを得る段階とを備え、
前記金属ナノ粒子が、銀、金、白金、銅、及びアルミニウムからなるグループから選択された金属を含む、
方法。 - ラマン分光法により試料を分析する方法であって、
金属層がその上に配置されている基質を準備する段階と、
金属ナノ粒子を含む水溶液を準備する段階と、
前記溶液に塩化リチウムを加えて、増感した金属ナノ粒子溶液を生成する段階と、
前記試料中の標的検体をラマン分光法により検出できるように、前記試料と前記増感した金属ナノ粒子溶液との混合物を、前記基質に接触させる段階と、
前記試料のラマンスペクトルを得る段階とを備え、
前記金属ナノ粒子が、銀、金、白金、銅、及びアルミニウムからなるグループから選択された金属を含む、
方法。 - 前記塩化リチウムが前記金属ナノ粒子を含む前記水溶液に加えられる前に、前記試料を、前記金属ナノ粒子溶液に接触させる、
請求項10または請求項11に記載の方法。 - 前記塩化リチウムが前記金属ナノ粒子を含む前記溶液に加えられた後で、前記試料を、前記金属ナノ粒子溶液に接触させる、
請求項10または請求項11に記載の方法。 - ラマン分光法により試料を分析する方法であって、
金属ナノ粒子が被覆された基質を準備する段階と、
前記基質に塩化リチウムを加えて、ラマン活性基質を生成する段階と、
前記試料中の標的検体をラマン分光法により検出できるように、分析される前記試料を含む水溶液を、前記ラマン活性基質に接触させる段階と、
前記試料のラマンスペクトルを得る段階とを備え、
前記金属ナノ粒子が、銀、金、白金、銅、及びアルミニウムからなるグループから選択された金属を含む、
方法。 - ラマン分光法により試料を分析する方法であって、
表面の少なくとも一部に金属層が配置されており、多孔質シリコンを含む基質を準備する段階と、
塩化リチウムを用いて、前記金属層を活性化させる段階と、
前記試料中の標的検体をラマン分光法により検出できるように、分析される前記試料を含む水溶液を、活性化した前記金属層に接触させる段階と、
前記試料のラマンスペクトルを得る段階とを備え、
前記金属層が、銀、金、白金、銅、及びアルミニウムからなるグループから選択された金属を含む、
方法。 - 前記多孔質シリコンは、ナノ結晶シリコンから構成される、
請求項15に記載の方法。 - 前記ラマン分光法が、表面増感ラマン分光法、表面増感共鳴ラマン分光法、ハイパーラマン分光法、及びコヒーレントアンチストークスラマン分光法からなるグループから少なくとも1つ以上選択される、
請求項10から請求項16までの何れか一項に記載の方法。 - 前記標的検体が、アミノ酸、ペプチド、ポリペプチド、タンパク質、糖タンパク、リポタンパク質、ヌクレオシド、ヌクレオチド、オリゴヌクレオチド、核酸、デオキシリボース核酸、リボース核酸、ペプチド核酸、糖、炭水化物、オリゴ糖、多糖類、脂肪酸、脂質、ホルモン、代謝体、サイトカイン、ケモカイン、受容体、神経伝達物質、抗原、アレルゲン、抗体、基質、代謝体、共同因子、阻害物質、薬物、調合剤、栄養素、プリオン、毒素、毒薬、火薬、殺虫剤、化学兵器、バイオハザード剤、バクテリア、ウイルス、放射性元素、ビタミン、複素環芳香族化合物、発がん性物質、突然変異原、麻酔薬、アンフェタミン、バルビツール酸塩、幻覚剤、廃棄物、汚染物質、量子ドット、あるいは染料からなるグループから選択される、
請求項10から請求項17までの何れか一項に記載の方法。 - 前記標的検体が、ヌクレオシド、ヌクレオチド、オリゴヌクレオチド、核酸、アミノ酸、ペプチド、ポリペプチド、及びたんぱく質からなるグループから選択される、
請求項10から請求項18までの何れか一項に記載の方法。 - ラマン分光法による試料の分析に用いる製造品であって、
金属ナノ粒子を含む水溶液に塩化リチウムを加えて得られた、増感した金属ナノ粒子溶液を有し、
前記金属ナノ粒子が、銀、金、白金、銅、及びアルミニウムからなるグループから選択された金属を含み、
試料中の標的検体をラマン分光法により検出できるように、前記増感した金属ナノ粒子溶液に、前記試料を接触させることで、前記試料のラマンスペクトルが得られる、
製造品。 - ラマン分光法による試料の分析に用いる製造品であって、
表面の少なくとも一部に金属層が配置されており、多孔質シリコンを含む基質を有し、
前記金属層は、銀、金、白金、銅、及びアルミニウムからなるグループから選択された金属を含み、
前記金属層は、塩化リチウムを用いて活性化され、
試料中の標的検体をラマン分光法により検出できるように、活性化された前記金属層に、分析される前記試料を含む水溶液を接触させることで、前記試料のラマンスペクトルが得られる、
製造品。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/387,750 US7318171B2 (en) | 2003-03-12 | 2003-03-12 | Policy-based response to system errors occurring during OS runtime |
PCT/US2004/002989 WO2004085988A2 (en) | 2003-03-12 | 2004-02-04 | Chemical enhancement in surface enhanced raman scattering using lithium chloride |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006514309A JP2006514309A (ja) | 2006-04-27 |
JP4603487B2 true JP4603487B2 (ja) | 2010-12-22 |
Family
ID=40875117
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005518574A Expired - Fee Related JP4603487B2 (ja) | 2003-03-12 | 2004-02-04 | リチウム塩を用いた表面増感ラマン分光法の化学増感 |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1606610A2 (ja) |
JP (1) | JP4603487B2 (ja) |
CN (1) | CN1934438A (ja) |
WO (1) | WO2004085988A2 (ja) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050147980A1 (en) * | 2003-12-30 | 2005-07-07 | Intel Corporation | Nucleic acid sequencing by Raman monitoring of uptake of nucleotides during molecular replication |
US7583379B2 (en) | 2005-07-28 | 2009-09-01 | University Of Georgia Research Foundation | Surface enhanced raman spectroscopy (SERS) systems and methods of use thereof |
GB0605752D0 (en) * | 2006-03-23 | 2006-05-03 | Univ Lincolnshire The | Preparation of stable silver colloids |
JP5110254B2 (ja) * | 2006-10-10 | 2012-12-26 | 富士レビオ株式会社 | 蛍光測定法と、蛍光測定のための測定用チップ及びその製造方法 |
US9689801B2 (en) | 2009-12-22 | 2017-06-27 | Agency For Science, Technology And Research | SERS-based analyte detection |
US9063836B2 (en) * | 2010-07-26 | 2015-06-23 | Intel Corporation | Methods and apparatus to protect segments of memory |
GB201307013D0 (en) * | 2013-04-18 | 2013-05-29 | Renishaw Diagnostics Ltd | Seers based assays for oligonucleotides |
JP2014228323A (ja) * | 2013-05-20 | 2014-12-08 | ウシオ電機株式会社 | 検査方法、センサ |
JP2014228321A (ja) * | 2013-05-20 | 2014-12-08 | ウシオ電機株式会社 | 検査方法 |
JP2014228322A (ja) * | 2013-05-20 | 2014-12-08 | ウシオ電機株式会社 | センサ、検査方法 |
KR101494131B1 (ko) | 2014-02-27 | 2015-02-16 | 숭실대학교산학협력단 | 은나노 구조체와 라만 분광법을 이용한 진균독소 시트리닌 검출방법 |
CN104568908B (zh) * | 2015-02-06 | 2017-12-01 | 上海师范大学 | 基于表面增强拉曼散射的高效测定谷物中微量呕吐毒素的新方法 |
CN107167834B (zh) * | 2017-07-21 | 2018-12-14 | 东南大学 | 检测热中子辐射的sers活性基底及其制备方法和应用 |
JP7190277B2 (ja) * | 2018-07-31 | 2022-12-15 | 浜松ホトニクス株式会社 | 被検体分析方法 |
CN109939664A (zh) * | 2019-04-16 | 2019-06-28 | 天津工业大学 | 一种多尺度纳微米氧化铝纤维光催化剂载体的制备方法 |
CN110579465A (zh) * | 2019-10-24 | 2019-12-17 | 汎锶科艺股份有限公司 | 二硫代氨基甲酸盐类农药的检测方法 |
JP7344140B2 (ja) * | 2020-01-27 | 2023-09-13 | 浜松ホトニクス株式会社 | 細胞分析方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002099982A2 (en) * | 2001-03-01 | 2002-12-12 | Illumina, Inc. | Methods for improving signal detection from an array |
AU2002239726A1 (en) * | 2001-05-25 | 2002-12-09 | Northwestern University | Non-alloying core shell nanoparticles |
US20040142484A1 (en) * | 2002-09-30 | 2004-07-22 | Intel Corporation | Spectroscopic analysis system and method |
-
2004
- 2004-02-04 EP EP04749311A patent/EP1606610A2/en not_active Withdrawn
- 2004-02-04 WO PCT/US2004/002989 patent/WO2004085988A2/en active Application Filing
- 2004-02-04 JP JP2005518574A patent/JP4603487B2/ja not_active Expired - Fee Related
- 2004-02-04 CN CN200480006205.5A patent/CN1934438A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2004085988A2 (en) | 2004-10-07 |
CN1934438A (zh) | 2007-03-21 |
WO2004085988A3 (en) | 2004-11-04 |
EP1606610A2 (en) | 2005-12-21 |
JP2006514309A (ja) | 2006-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4603487B2 (ja) | リチウム塩を用いた表面増感ラマン分光法の化学増感 | |
Huang et al. | SERS discrimination of single DNA bases in single oligonucleotides by electro-plasmonic trapping | |
Wang et al. | Highly sensitive and automated surface enhanced Raman scattering-based immunoassay for H5N1 detection with digital microfluidics | |
Oh et al. | Performance metrics and enabling technologies for nanoplasmonic biosensors | |
US7019828B2 (en) | Chemical enhancement in surface enhanced raman scattering using lithium salts | |
Wang et al. | Surface-enhanced Raman spectroscopy at single-molecule scale and its implications in biology | |
Wang et al. | Selectivity/specificity improvement strategies in surface-enhanced Raman spectroscopy analysis | |
Muehlethaler et al. | Review of surface enhanced Raman scattering applications in forensic science | |
Han et al. | Portable kit for identification and detection of drugs in human urine using surface-enhanced Raman spectroscopy | |
Penn et al. | Accelerated surface-enhanced Raman spectroscopy (SERS)-based immunoassay on a gold-plated membrane | |
Barahona et al. | An aptasensor based on polymer-gold nanoparticle composite microspheres for the detection of malathion using surface-enhanced raman spectroscopy | |
JP5792614B2 (ja) | 被覆ナノ粒子を使用した高感度免疫学的検定 | |
US20050186565A1 (en) | Method and spectral/imaging device for optochemical sensing with plasmon-modified polarization | |
Kant et al. | Surface-enhanced Raman scattering spectroscopy and microfluidics: Towards ultrasensitive label-free sensing | |
Bishnoi et al. | SERS biodetection using gold–silica nanoshells and nitrocellulose membranes | |
US20070155020A1 (en) | Detection of chemical analytes by array of surface enhanced Raman scattering reactions | |
Tycova et al. | Recent strategies toward microfluidic‐based surface‐enhanced Raman spectroscopy | |
Eskandari et al. | A review of applications of surface-enhanced raman spectroscopy laser for detection of biomaterials and a quick glance into its advances for COVID-19 investigations | |
März et al. | Fluorescence dye as novel label molecule for quantitative SERS investigations of an antibiotic | |
Hakonen | Plasmon enhancement and surface wave quenching for phase ratiometry in coextraction-based fluorosensors | |
Peveler et al. | Nanoparticles in explosives detection–the state-of-the-art and future directions | |
Song et al. | Gold-modified silver nanorod arrays for SERS-based immunoassays with improved sensitivity | |
Brown et al. | Optimization of the preparation of glass-coated, dye-tagged metal nanoparticles as SERS substrates | |
Syme et al. | Quantitative characterization of individual microdroplets using surface-enhanced resonance raman scattering spectroscopy | |
Jin et al. | Facile amplification of solution-state surface-enhanced Raman scattering of small molecules using spontaneously formed 3D nanoplasmonic wells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080507 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080805 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080812 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080904 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090317 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090617 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20091124 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100324 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100325 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20100416 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100622 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100820 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100914 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20101001 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131008 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |